Acute Stroke Animal Models & CRO Services

Acute Stroke Animal Models & CRO Services - Preclinical Research Stroke is the third leading cause of death and disability in the U.S., with approximate 800,000 new cases per year. Eighty-five percent of strokes are "ischemic," due to occlusion of a brain artery, causing death of brain tissue (infarction) supplied by that artery.

Acute stroke treatments are given within a few hours after stroke onset. Such treatments include thrombolytic ("clot-busting") and tissue-sparing ("neuroprotective") agents. Biotrofix is highly experienced in rodent (mouse and rat) models of acute focal stroke, including suture-occlusion, Chen, Tamura, and embolic methods. These models are suitable for testing of new thrombolytic and neuroprotective strategies. Endpoints of these studies include histology (infarct volume determination) and behavioral testing.

Download ACUTE STROKE NEUROPROTECTION MODEL (.pdf)

Home The Company Preclinical Research Services The Team News Publications Contact Us Site Map

Biotrofix is a premier preclinical contract research organization specializing in animal models of CNS, cardiac and vascular disease. With years of experience, both academic, commercial, clients throughout the biotech and pharmaceutical industries, Biotrofix delivers industry-leading preclinical CRO services, including rodent models of acute stroke and stroke recovery, preclinical CRO services for Alzheimer's Disease, transgenic animal models for ALS, as well as CRO services for brain injury, preclinical CRO services for spinal cord injury and related cardiac drug discovery and development.